's () Rory Nealon tells Proactive that the company is actively seeking to expand its commercial portfolio following the success of its Lojuxta treatment.
The pharmaceutical firm reported a narrowed loss before tax of €11.3mln for the first half of the year, less than a €13.8mln loss previously, while revenues grew to €7mln from €6.1mln.
Revenues were boosted by a 14.6% increase in sales of the Lojuxta drug to €6.6mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE